The findings of our study suggest that the presence of the CYP2C9*2 allele (and its corresponding genotypes CYP2C9*1/*2 and CYP2C9*2/*2) plays a key role in predisposing patients receiving sulphonylurea treatment toward hypoglycaemia. The gene discussed is CYP2C9; the disease is Hypoglycemia.